




Originalbilder Manuskript

Fig. 1 D
SW982/WT



MCL-1



BAX

Fig. 1 D
SW982/WT









Fig. 1 D
SW982/WT



BAK




GAPDH

GAPDH*



Fig. 1 D

SW982/BAK^{KO}
SW982/BAX^{KO}



MCL-1 (SW982/BAK^{KO})

MCL-1 (SW982/BAK^{KO})





BOK (SW982/BAK^{KO})

BOK (SW982/BAK^{KO})

BAX (SW982/BAK^{KO})

BAX (SW982/BAK^{KO})

Fig. 1 D
SW982/BAK^{KO}
SW982/BAX^{KO}





NOXA (SW982/BAK^{KO})

NOXA (SW982/BAX^{KO})

Fig. 1 D



SW982/BAK^{KO}

SW982/BAX^{KO}



BCL-2 (SW982/BAK^{KO})

BCL-2 (SW982/BAK^{KO})





BAK (SW982/BAX^{KO})

BAK (SW982/BAX^{KO})

Fig. 1 D

SW982/BAK^{KO}

SW982/BAX^{KO}



GADPH* (SW982/BAX^{KO})

GADPH** (SW982/BAX^{KO})

GAPDH (SW982/BAK^{KO})

GAPDH* (SW982/BAK^{KO})

Fig. 2 G-I
SW982/NOXA^{KD}








Fig. 2 G-I
SW982/NOXA^{KD}



NOXA (Fig. 2 G)

NOXA (Fig. 2 H)

NOXA (Fig. 2 I)



β -ACTIN (Fig. 2 G)

β -ACTIN (Fig. 2 H)

β -ACTIN (Fig. 2 I)

Fig. 3 A
SW982/WT






Fig. 3 A
SW982/WT






Fig. 3 C
SW982/WT





β-ACTIN





NOXA

Fig. 3 C
SW982/WT




MCL-1




TP53

Fig. 3 D

SW982/WT




NOXA





β -ACTIN

Fig. 3 D
SW982/WT



MCL-1

NOXA



β -ACTIN

Fig. 3 E
SW982/WT







Fig. 3 F
SW982/WT






Fig. 3 F
SW982/WT






Fig. 3 H
SW982/WT




β -ACTIN





NOXA

Fig. 3 H
SW982/WT



MCL-1



TP53

Fig. 4 A
SW982/WT











Fig. 4 E
SW982/WT



(P)-eIF2a



ATF3

Fig. 4 E
SW982/WT










Fig. 4 E
SW982/WT




β -ACTIN





eIF2a

Fig. 5 A
SW982/WT





NOXA



β -ACTIN

Suppl. Fig. 1 E

SW982/WT





β -ACTIN (Suppl.Fig. 1 E)

β -ACTIN (Suppl.Fig. 1 F)

β -ACTIN (Suppl.Fig. 1 G)

Suppl. Fig. 1 E-G

SW982/WT







NOXA (Suppl.Fig. 1 E)

NOXA (Suppl.Fig. 1 F)

NOXA (Suppl.Fig. 1 G)



Suppl. Fig. 1 I

HCT116





Suppl. Fig. 1 I

HCT116



BAX





BAK

Suppl. Fig. 2 H

H1299



H1299+p53									
	-	+	-	+	-	+	-	+	15 μ M ABT-199
	-	-	+	+	-	-	-	-	5 nM Bortezomib
	-	-	-	-	+	+	-	-	5 nM Carfilzomib
	-	-	-	-	-	-	+	+	5 nM Ixazomib
kDa	+	+	+	+	+	+	+	+	10 μ M QVD-OPh



Suppl. Fig. 2 H

H1299



H1299+p53									
	-	+	-	+	-	+	-	+	15 μ M ABT-199
	-	-	+	+	-	-	-	-	5 nM Bortezomib
	-	-	-	-	+	+	-	-	5 nM Carfilzomib
	-	-	-	-	-	-	+	+	5 nM Ixazomib
kDa	+	+	+	+	+	+	+	+	10 μ M QVD-OPh



Suppl. Fig. 2 H

H1299



		H1299+p53							
	-	+	-	+	-	+	-	+	15 μ M ABT-199
	-	-	+	+	-	-	-	-	5 nM Bortezomib
	-	-	-	-	+	+	-	-	5 nM Carfilzomib
	-	-	-	-	-	-	+	+	5 nM Ixazomib
kDa	+	+	+	+	+	+	+	+	10 μ M QVD-OPh



Suppl. Fig. 2 H

H1299



H1299+p53									
	-	+	-	+	-	+	-	+	15 μ M ABT-199
	-	-	+	+	-	-	-	-	5 nM Bortezomib
	-	-	-	-	+	+	-	-	5 nM Carfilzomib
	-	-	-	-	-	-	+	+	5 nM Ixazomib
kDa	+	+	+	+	+	+	+	+	10 μ M QVD-OPh



Suppl. Fig. 2 H


H1299

H1299+p53									
	-	+	-	+	-	+	-	+	15 μ M ABT-199
	-	-	+	+	-	-	-	-	5 nM Bortezomib
	-	-	-	-	+	+	-	-	5 nM Carfilzomib
	-	-	-	-	-	-	+	+	5 nM Ixazomib
kDa	+	+	+	+	+	+	+	+	10 μ M QVD-OPh




Suppl. Fig. 2 H

H1299




		H1299								
kDa	H1299+p53	-	+	-	+	-	+	-	+	15 μ M ABT-199
		-	-	+	+	-	-	-	-	5 nM Bortezomib
		-	-	-	-	+	+	-	-	5 nM Carfilzomib
		-	-	-	-	-	-	+	+	5 nM Ixazomib
		+	+	+	+	+	+	+	+	10 μ M QVD-OPh




Suppl. Fig. 2 H

H1299





		H1299								
H1299+p53		-	+	-	+	-	+	-	+	15 μ M ABT-199
		-	-	+	+	-	-	-	-	5 nM Bortezomib
		-	-	-	-	+	+	-	-	5 nM Carfilzomib
		-	-	-	-	-	-	+	+	5 nM Ixazomib
		+	+	+	+	+	+	+	+	10 μ M QVD-OPh



Suppl. Fig. 2 H
H1299



		H1299								
		-	+	-	+	-	+	-	+	15 μ M ABT-199
		-	-	+	+	-	-	-	-	5 nM Bortezomib
		-	-	-	-	+	+	-	-	5 nM Carfilzomib
		-	-	-	-	-	-	+	+	5 nM Ixazomib
kDa	H1299+p53	+	+	+	+	+	+	+	+	10 μ M QVD-OPh



Suppl. Fig. 2 H
H1299


		H1299								
		-	+	-	+	-	+	-	+	15 μ M ABT-199
		-	-	+	+	-	-	-	-	5 nM Bortezomib
		-	-	-	-	+	+	-	-	5 nM Carfilzomib
		-	-	-	-	-	-	+	+	5 nM Ixazomib
		+	+	+	+	+	+	+	+	10 μ M QVD-OPh

kDa H1299+p
53




Suppl. Fig. 2 H


H1299



		H1299								
kD	H1299+p53	-	+	-	+	-	+	-	+	15 μ M ABT-199
		-	-	+	+	-	-	-	-	5 nM Bortezomib
		-	-	-	-	+	+	-	-	5 nM Carfilzomib
		-	-	-	-	-	-	+	+	5 nM Ixazomib
	a	+	+	+	+	+	+	+	+	10 μ M QVD-OPh





Suppl. Fig. 3 A
SW982/WT



Suppl. Fig. 3 A

SW982/WT



Suppl. Fig. 3 B

SW982/WT

